A simple comparison of PD-1/CTLA-4 BSABs with bintrafusp alfa suggested that PD-1/CTLA-4 BSABs had increased efficacy in patients with recurrent or metastatic NPC who have failed second-line or above chemotherapy (ORR, 30% vs. 23.7%), particularly in patients with high PD-L1 expression (ORR, 57.1%). The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.